Industry News

Masimo announced today that the Masimo Foundation has co-founded the United for Oxygen Alliance, as part of a Clinton Global Initiative commitment. The first-of-its-kind public-private partnership, announced this week at the final CGI Annual Meeting, will seek to expand access to medical oxygen and pulse oximetry for women..."/>
Masimo Foundation Co-Founds United for Oxygen Alliance
Molina Healthcare Inc., UnitedHealthcare, Blue Cross Blue Shield of New Mexico and Amerigroup-- have been told they owe money. The report seemed to catch..."/>
Report of back taxes owed surprises health insurance executives [Albuquerque Journal, N.M.]
Molina Healthcare Inc., UnitedHealthcare, Blue Cross Blue Shield of New Mexico and Amerigroup-- have been told they owe money. The report seemed to catch..."/>
Report of back taxes owed surprises health insurance executives [Albuquerque Journal, N.M.]
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its observance of The FH Foundation’ s annual Familial Hypercholesterolemia Awareness Day.. Chief Executive Officer Mary Szela said, "We share The FH Foundation’ s mission of increasing awareness of FH, including homozygous FH, a very serious and often..."/>
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
Community Health Systems, which owns Porter Regional Hospital in Valparaiso, LaPorte Hospital and Starke Hospital in Knox, has suffered major financial losses and seen its stock price drop significantly over the course of the past year. "Community Health Systems, Inc. announced today that the Company, with the assistance of advisors, is exploring..."/>
Owner of Porter, LaPorte hospitals exploring sale [The Times, Munster, Ind.]
Apptio's stock popped up 41 percent Friday in the Bellevue technology company's first day of trading. Apptio raised about $96 million in its public debut-- a hotly anticipated move for the 9- year-old company that has raised at least $136 million from investors throughout its life. Apptio priced its shares at $16 each, above its expected range of $13 to $15, and closed its first day of trading up $6.55 at $22.55."/>
Apptio's stock soars as Bellevue tech company makes trading debut [The Seattle Times]
Amgen today announced that the U.S. Food and Drug Administration has approved AMJEVITA™ across all eligible indications of the reference product, Humira ®. AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic..."/>
FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases
Medical Facilities Corporation, today announced that it has closed its previously announced transaction to acquire, in stages, an indirect 83 percent interest in Unity Medical and Surgical Hospital, a physician-owned medical and surgical hospital located in Mishawaka, Indiana. The signing of a letter of intent to acquire the hospital and the acquisition of the underlying real estate was announced in a press release dated July 15, 2016.."/>
Medical Facilities Corporation Acquires Physician-Owned Hospital in Indiana
Unilife Corporation announced today that it has received a letter from The NASDAQ Stock Market LLC notifying the Company that it is not in compliance with NASDAQ Listing Rule 5250 (c) because it has not filed its Annual Report on Form 10- K for the period ended June 30, 2016 in a timely manner with the Securities and Exchange Commission. NASDAQ Listing Rule 5250 (c) requires listed companies to timely file all required periodic financial reports..."/>
Unilife Corporation Announces Receipt of Delinquency Letter from NASDAQ Relating to Fiscal 2016 Form 10-K
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced the filing with the U.S. Securities and Exchange Commission of the company’ s Forms 10- Q for the three months ended March 31, 2016, and for the three and six months ended June 30, 2016.. KaloBios is now current with its SEC periodic reporting requirements."/>
KaloBios Now Current on SEC Periodic Filings
Sunshine Heart, Inc. today announced that on September 21, 2016, it received a letter from the Nasdaq Listing Qualifications Staff indicating that the Company did not timely demonstrate compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. In accordance with the Nasdaq listing rules, the Company intends to request a hearing before the Nasdaq hearings panel to present its plan to demonstrate..."/>
Sunshine Heart Announces Receipt of Nasdaq Staff Determination; To Request Hearing
Allergan plc today announced the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA ® Cohesive breast implants, offering women undergoing reconstruction, augmentation or revision surgery a new breast shaping option that combines a high gel fill ratio and Allergan's highly cohesive gel 1,2 for a customized result. The new NATRELLE INSPIRA ® Cohesive line of breast implants is the newest..."/>
Allergan Announces FDA Approval of NATRELLE INSPIRA® Cohesive Breast Implants
AMN Healthcare Services, Inc. announced today that its subsidiary, AMN Healthcare, Inc., priced its previously announced private offering of senior notes due 2024 and increased the offering size from $300 million to $325 million. The Senior Notes will bear an interest rate of 5.125% per annum and will be issued at 100.00% of their face value. The Senior Notes will be guaranteed by the Company's affiliates that guarantee the Company's credit..."/>
AMN Healthcare Announces Pricing Of Senior Notes Offering
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that as previously disclosed in its Annual Report on Form 10- K for the year ended June 30, 2016, which was filed on September 19, 2016 with the Securities and Exchange Commission, the audited financial..."/>
Palatin Technologies Receives Audit Opinion with Going Concern Explanation
Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, at 9:30 a.m. Eastern time in New York, NY, and will discuss Ignyta’ s Rx/Dx approach and review recent updates from ongoing clinical trials of the company’ s robust pipeline of molecularly targeted therapies."/>
Ignyta to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced the closing of its previously announced underwritten public offering of 6,152,500 shares of its common stock, including 802,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a..."/>
Aquinox Announces Closing of $75.4 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Endo International soared Friday after the drug maker named Paul V. Campanelli as president and CEO effective immediately. The company, with U.S. headquarters in Malvern, said that Rajiv De Silva has stepped down as chief executive officer and a board member. Endo shares were up 17.18 percent, or $3.48, to $23.74 at noon."/>
Endo names new CEO, stock surges [Philly.com]
Indivior, and MonoSol Rx conspired to block generic competitors for Suboxone by switching the drug from a tablet to a dissolving film."/>
Maryland among 36 states suing makers of heroin addiction treatment drug Suboxone for antitrust violations [The Baltimore Sun]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology804 Articles
Consumer Discretionary695 Articles
Financials534 Articles
Health Care489 Articles
Industrials452 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.